OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Infectious Diseases is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Ordinary people in extraordinary times	1895
Infectious disease surveillance update	1395
Chronicling PEPFAR's work in Africa	971
A step forward in the journey towards hookworm vaccines	832
Adaora “Ada” Alise Adimora	710
Reflecting on lessons from the 2014–16 Ebola virus outbreak	614
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	606
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	526
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	462
The lasting lessons of mpox: infection, vaccination, and immune memory	393
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	333
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	309
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	307
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	296
Shaping opportunities for future clinical trials in tuberculosis	267
Kyasanur Forest disease: an emerging arboviral threat	266
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	262
Highlights from the sixth ESCMID Conference on Vaccines	256
COVID-19 vaccination protects children and adolescents	254
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	253
Research in brief	250
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	248
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	247
Environment and infectious diseases	239
Surge of cutaneous leishmaniasis in Pakistan	232

DNDi receives Dutch funding boost	228
Research in brief	225
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	213
Attention to skin-related neglected tropical diseases	211
HIV vaccine trial failure	210
Transitioning to endemicity with COVID-19 research	203
The superiority of bivalent over monovalent booster vaccines	200
A patient with secondary syphilis following incomplete treatment of primary infection	200
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	197
Infectious disease surveillance update	193
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children	190
Threat of HIV and tuberculosis drug resistance after US funding cuts	187
Promoting diversity and equity in publishing	186
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	180
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	179
Measles immunity gaps and outbreak risk in a shifting landscape	176
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	175
Correction to Lancet Infect Dis 2025; 25: e280–93	172
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	171
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	168
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	166
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	165
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	162
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	162
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	161
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	160
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	160
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	158
Updated criteria for paediatric sepsis and septic shock	158
The next chapter for Africa's genomic initiatives	152
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	148
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	148
The importance of understanding the infectious microenvironment	147
Mpox in people with past infection or a complete vaccination course: a global case series	146
Listeria monocytogenes: a rare, deadly cause of peritonitis	140
Research in brief	139
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	139
Research in brief	137
Global cholera resurgence—a preventable tragedy	137
New flavours of tuberculosis treatment for children	134
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	133
Correction to Lancet Infect Dis 2025; 25: e47–58	133
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	132
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	131
Addressing the shortage of cholera vaccines	130
Post-viral sequelae of COVID-19 and influenza	128
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	127
The implications of mpox breakthrough infections on future vaccination strategies	127
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study	127
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	127

A new monoclonal in the arMAMentarium against malaria	125
Infectious disease surveillance update	123
Theresa Ochoa—staying on top of infectious diseases in Peru	123
Research in brief	122
Correction to Lancet Infect Dis 2025; 25: e622	121
RSV prevention: public health lessons from the southern hemisphere	120
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	119
Worrying lack of funding for tuberculosis	118
Full-dose NSAIDs at the first sign of respiratory infection?	116
Severe influenza: is there a role for antiviral combinations?	115
Correction to Lancet Infect Dis 2023; 23: e469	114
Tuberculosis recovery in Georgia: implementing more by 24	113
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	111
Election of Regional Director for the Western Pacific	109
Curing chronic hepatitis B virus infection	108
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	108
History and evolution of tuberculosis and global health	106
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	106
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	106
Emil Gotschlich	106
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	105
Supporting healthcare access for refugees and migrants	105
Is combination antiviral therapy for influenza the optimal approach?	105
Interplay of infection and vaccination in long-term protection from COVID-19	101
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	99
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	97
Serpiginous-like choroiditis in ocular tuberculosis	97
COVID-19 mortality in Africa and Asia – Authors' reply	96
Elisabeth Presterl—always looking forward	96
High-dose primaquine reduces vivax relapses: time for change	96
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	95
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	94
WHO's first global infection prevention and control report	94
The response of mpox-associated inflammatory syndrome to steroid therapy	93
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	93
Research in brief	93
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	92
What can be learnt from the world's first national vaccination programme against gonorrhoea	91
The global burden of cryptococcosis—a neglected tropical disease?	89
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	88
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	88
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	87
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	87
Super-spreaders: a historical review	87
Twin threats: climate change and zoonoses	87
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	84
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	84
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study	83
Vaccine and surveillance implications of dengue underdetection	83
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	82
WHO Pathogen X conference	82
Patient-centred approaches for drug-resistant tuberculosis	81
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	81
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	80
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	80
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	80
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	79
Infectious disease surveillance update	78
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	78
Spreading awareness on lymphatic filariasis	77
Correction to Lancet Infect Dis 2021; 21: 929–38	77
Lessons learnt from conducting a randomised clinical trial in eumycetoma	76
doxyPEP: a controversial new tool against STIs	76
COVID-19 mortality in Africa and Asia	76
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	75
A step closer to elimination of meningococcal disease	75
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	74
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	74
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	74
Advancing integration: progress reported for skin NTDs	74
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	73
Pui-Ying Iroh Tam	71
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	71
Hong Kong's fifth COVID-19 wave—the worst yet	71
Social workers and neglected tropical diseases	70
Moxidectin versus ivermectin for strongyloidiasis control	70
Outbreaks compound Brazil's flooding disaster	70
Research in brief	69
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	69
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	69

Vaccine pragmatism in the 21st century	68
Ivermectin for malaria control in mass drug administration programmes	68
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	68
Highlights from ECCMID 2022	67
Human ocular thelaziosis—a zoonosis of the eye	67
Next-generation malaria subunit vaccines to reduce disease burden in African children	67
Is the end of gonorrhoea in sight?	66
On the frontline during the COVID-19 pandemic	66
Amal Saif Al-Maani—fighting antimicrobial resistance	66
Correction to Lancet Infect Dis 2023; 23: e259–65	66
The urgent need to scale-up fungal diagnostics in Africa	66
Sir Michael Anthony Epstein	65
Imprinted hybrid immunity against XBB reinfection	64
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	64
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	64
A tale of potential mpox reinfection	64
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	64
Sleeping sickness: time for dreaming	64
The origin of SARS-CoV-2 variants of concern	63
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	63
Clindamycin-resistant Streptococcus pyogenes in Chinese children	63
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	63
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	62
A rare case of rabies-like Australian bat lyssavirus infection	61
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	61
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	60
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	60
Gender and geographical representation at infectious diseases and clinical microbiology conferences	60
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	60
Re-emergence of Oropouche virus in Brazil and Latin America	59
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	59
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	59
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	58
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	58
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	57
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	57
Child-friendly rifapentine formulation is a game changer	57
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	56
DoxyPEP: thinking towards implementation	56
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	55
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	55
A shared history	54
Understanding the immunogenicity of RTS,S in infants	54
Alexandra King—promoting Indigenous self-determination	54
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	54
Correction to Lancet Infect Dis 2025; 25: e11–12	54
Deaths of unknown cause in DR Congo	53
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	53
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	53
Antiblackness in the Ebola response in Sierra Leone	52
COVID-19 versus influenza: the need to align policies with COVID-19 realities	52
A vanquished threat or a cautionary tale?	51
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	51
Experts react to SAGO's preliminary report	51
Revisiting oral antivirals for COVID-19 in the hospital setting	51
A new formulation of praziquantel to achieve schistosomiasis elimination	50
Learning and confirming in publicly funded antiviral trials	50
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	50
Antibiotic stewardship in the real world	49
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	49
Randomised controlled trials for mpox in endemic countries	49
Developing the EAVE III platform for future health crises	49
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	49
Correction to Lancet Infect Dis 2023; 23: 789	49
Lyda Osorio—tackling South America's infectious diseases	48
Monkeypox trial to begin in DR Congo	48
Correction to Lancet Infect Dis 2025; 25: 764–74	48
Lien Jih-ching	48
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	48
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	48
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	48
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	48
Candida albicans fungal ball in the eyeball	48
Global measles cases up 20% in 2023	48
Antibody durability at 1 year after Sputnik V vaccination	47
Humanitarian crisis in Tigray amidst civil war	47
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	47
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	46
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	46
Mpox control strategies: using behaviour change to complement, not replace, vaccination	46
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	46
Salmonella Typhimurium outbreak linked to chocolate	46
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	45
Struggling with a new dengue epidemic in Nepal	45
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	44
A new key-player for onchocerciasis elimination	44
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study	44
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	44
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	44
Correction to Lancet Infect Dis 2025; published online Oct 29. https://doi.org/10.1016/S1473-3099(25)00466-9	44
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	44
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	43
What is the pandemic potential of avian influenza A(H5N1)?	43
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-base	43
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	43